WO2024254017A8 - Stapled peptides and methods thereof - Google Patents

Stapled peptides and methods thereof

Info

Publication number
WO2024254017A8
WO2024254017A8 PCT/US2024/032319 US2024032319W WO2024254017A8 WO 2024254017 A8 WO2024254017 A8 WO 2024254017A8 US 2024032319 W US2024032319 W US 2024032319W WO 2024254017 A8 WO2024254017 A8 WO 2024254017A8
Authority
WO
WIPO (PCT)
Prior art keywords
methods
stapled peptides
stapled
peptides
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/032319
Other languages
French (fr)
Other versions
WO2024254017A2 (en
WO2024254017A3 (en
Inventor
Keith William ORFORD
Lihua Yu
Theodore Anael MARTINOT
Jonathan Barry Hurov
Yaguang Si
Xinwei Han
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Parabilis Medicines Inc
Original Assignee
Parabilis Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parabilis Medicines Inc filed Critical Parabilis Medicines Inc
Priority to CN202480050901.3A priority Critical patent/CN121620379A/en
Priority to AU2024284126A priority patent/AU2024284126A1/en
Priority to KR1020257041985A priority patent/KR20260035134A/en
Publication of WO2024254017A2 publication Critical patent/WO2024254017A2/en
Publication of WO2024254017A3 publication Critical patent/WO2024254017A3/en
Priority to IL325050A priority patent/IL325050A/en
Publication of WO2024254017A8 publication Critical patent/WO2024254017A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

Among other things, the present disclosure provides technologies including I-66 formulations, compositions, methods, etc. for treating various cancers.
PCT/US2024/032319 2023-06-06 2024-06-03 Stapled peptides and methods thereof Ceased WO2024254017A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN202480050901.3A CN121620379A (en) 2023-06-06 2024-06-03 Staple peptides and their methods
AU2024284126A AU2024284126A1 (en) 2023-06-06 2024-06-03 Stapled peptides and methods thereof
KR1020257041985A KR20260035134A (en) 2023-06-06 2024-06-03 Stapled peptide and method thereof
IL325050A IL325050A (en) 2023-06-06 2025-12-01 Stapled peptides and methods thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363471492P 2023-06-06 2023-06-06
US63/471,492 2023-06-06
US202363510357P 2023-06-26 2023-06-26
US63/510,357 2023-06-26

Publications (3)

Publication Number Publication Date
WO2024254017A2 WO2024254017A2 (en) 2024-12-12
WO2024254017A3 WO2024254017A3 (en) 2025-04-24
WO2024254017A8 true WO2024254017A8 (en) 2025-12-04

Family

ID=93794644

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/032319 Ceased WO2024254017A2 (en) 2023-06-06 2024-06-03 Stapled peptides and methods thereof

Country Status (5)

Country Link
KR (1) KR20260035134A (en)
CN (1) CN121620379A (en)
AU (1) AU2024284126A1 (en)
IL (1) IL325050A (en)
WO (1) WO2024254017A2 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012040459A2 (en) * 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
CN111372942A (en) * 2017-09-07 2020-07-03 弗格制药有限公司 β -catenin function modulating agents and methods thereof
MX2023014679A (en) * 2021-06-08 2024-01-15 Fog Pharmaceuticals Inc Stapled peptides and methods thereof.

Also Published As

Publication number Publication date
WO2024254017A2 (en) 2024-12-12
IL325050A (en) 2026-02-01
WO2024254017A3 (en) 2025-04-24
AU2024284126A1 (en) 2025-12-11
KR20260035134A (en) 2026-03-12
CN121620379A (en) 2026-03-06

Similar Documents

Publication Publication Date Title
CA3149406A1 (en) Novel anti-cldn18.2 antibodies
WO2020123300A3 (en) Kras variant mrna molecules
WO2023147594A3 (en) Irak degraders and uses thereof
EP4691554A3 (en) Glp-1r modulating compounds
EP4523751A3 (en) Glp-1r modulating compounds
EP4520393A3 (en) Carboxy-benzimidazole glp-1r modulating compounds
WO2021178749A3 (en) Anti-ccr8 agents
EP4491635A3 (en) Anti-ccr8 antibodies
AU2003303458A1 (en) Ampholytic copolymer and use thereof
EP2465520A3 (en) Epitope sequences
WO2004076644A3 (en) A composition for delivering an agent to a target cell and uses thereof
MX2023008423A (en) Novel anti-gremlin1 antibodies.
EP4428234A3 (en) Direct-to-library methods, systems, and compositions
AU2002217010A1 (en) Peptides, the production and use thereof for binding immunoglobulins
WO2021262597A3 (en) Lair-1-binding agents and methods of use thereof
EP4093764A4 (en) Multispecific antibodies, compositions comprising the same, and vectors and uses thereof
WO2024264017A3 (en) Irak degraders and uses thereof
MX2022015966A (en) Antibodies and methods for treating claudin-associated diseases.
WO2020180712A8 (en) Anti-tnfr2 antibodies and uses thereof
WO2021207948A9 (en) Anti-sars-cov-2 antibodies and uses thereof
WO2020235974A3 (en) Single base substitution protein, and composition comprising same
WO2024083925A3 (en) Novel anti-napi2b antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
WO2024254017A8 (en) Stapled peptides and methods thereof
WO2020102243A3 (en) In-flow photooxygenation of aminothienopyridinones generates novel ptp4a3 phosphatase inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: AU2024284126

Country of ref document: AU

Ref document number: 827542

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 827542

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 325050

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/A/2025/014547

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2024284126

Country of ref document: AU

Date of ref document: 20240603

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025026721

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 202517131530

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 202593535

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 325050

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2024819836

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 202517131530

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2024819836

Country of ref document: EP

Effective date: 20260107

ENP Entry into the national phase

Ref document number: 2024819836

Country of ref document: EP

Effective date: 20260107

WWE Wipo information: entry into national phase

Ref document number: 11202508234Y

Country of ref document: SG

WWP Wipo information: published in national office

Ref document number: 11202508234Y

Country of ref document: SG

ENP Entry into the national phase

Ref document number: 2024819836

Country of ref document: EP

Effective date: 20260107

ENP Entry into the national phase

Ref document number: 2024819836

Country of ref document: EP

Effective date: 20260107

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24819836

Country of ref document: EP

Kind code of ref document: A2